| Oct 1 |
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
|
| Sep 30 |
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
|
| Sep 21 |
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
|
| Sep 10 |
Altimmune spikes after presenting data for obesity drug
|
| Sep 10 |
CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
|
| Sep 10 |
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
|
| Sep 3 |
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
|
| Aug 27 |
Altimmune: Emerging Position In Competitive Space, But Risks Remain
|
| Aug 10 |
Altimmune First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Aug 10 |
Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript
|
